Volume | 219,816 |
|
|||||
News | - | ||||||
Day High | 31.80 | Low High |
|||||
Day Low | 31.215 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Agios Pharmaceuticals Inc | AGIO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
31.22 | 31.215 | 31.80 | 31.67 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
3,714 | 219,816 | $ 31.51 | $ 6,925,972 | - | 19.795 - 35.48 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
12:40:48 | 15 | $ 31.75 | USD |
Agios Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
1.78B | 56.19M | - | 26.82M | -352.09M | -6.27 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Agios Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AGIO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 29.10 | 33.02 | 28.71 | 30.70 | 805,485 | 2.65 | 9.11% |
1 Month | 29.19 | 33.02 | 27.14 | 29.59 | 657,295 | 2.56 | 8.77% |
3 Months | 22.71 | 35.48 | 22.23 | 29.51 | 762,777 | 9.04 | 39.81% |
6 Months | 20.76 | 35.48 | 19.795 | 25.85 | 727,764 | 10.99 | 52.94% |
1 Year | 22.28 | 35.48 | 19.795 | 25.72 | 582,115 | 9.47 | 42.50% |
3 Years | 55.14 | 62.155 | 16.75 | 31.38 | 597,961 | -23.39 | -42.42% |
5 Years | 56.90 | 62.155 | 16.75 | 36.88 | 641,905 | -25.15 | -44.20% |
Agios Pharmaceuticals Description
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval. |